The short version of melanocortin receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-19 and is reviewed periodically as new material appears.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility class | Soluble in water and aqueous buffers | Stock solutions often prepared in sterile water |
| Typical storage temperature | Minus twenty degrees Celsius or below | Dry powder, protected from light |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Ultraviolet detection near 214 nanometres |
| Common synonyms | PT-141 and bremelanotide | Code and generic name used interchangeably |
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
=== Traditional chemical synthesis === A large toolbox of chemical reactions is available for each step of the synthesis of a fine chemical. The reactions have been developed on laboratory scale by academia over the last two centuries and subsequently adapted to industrial scale, such as the manufacture of dyestuffs & pigments. Methods of Molecular Transformations describes 26,000 organic synthetic methods, about 10% of which are currently used on an industrial scale for fine chemicals production. Amination, condensation, esterification, Friedel–Crafts, Grignard, halogenation (especially chlorination), hydrogenation, and reduction (both catalytic and chemical) are the most frequently mentioned techniques on the websites of individual companies. Optically active cyanohydrins, cyclopolymerization, ionic liquids, nitrones, oligonucleotides, peptide (both liquid- and solid-phase), electrochemical reactions (like perfluorination) and steroid synthesis are promoted by only a limited number of companies. With the exception of some stereospecific reactions, particularly biotechnology, mastering these technologies does not represent a distinct competitive advantage. Most reactions can be carried out in standard multipurpose plants. The very versatile organometallic reactions (e.g., conversions with lithium aluminum hydride, boronic acids) may require temperatures as low as −100 °C (−148 °F), which can be achieved only in special cryogenic reaction units, either by using liquefied nitrogen as coolant or by installing a low-temperature unit.
Major depressive disorder (MDD) Post-traumatic stress disorder (PTSD) Generalized anxiety disorder (GAD) Social anxiety disorder (SAD) Obsessive–compulsive disorder (OCD) Panic disorder Neuropathic pain Fibromyalgia Chronic musculoskeletal pain Neuropathic pain involves the descending noradrenergic pathways, which help regulate pain signals. By increasing norepinephrine in these pathways, SNRIs can help reduce pain transmission independently of its antidepressant effects.
== Structure and function == In humans, BCATs are homodimers composed of two domains, a small subunit (residues 1-170) and a large subunit (residues 182-365). These subunits are connected by a short, looping connecting region (residues 171-181). Both subunits consist of four alpha-helices and a beta-pleated sheet. Structural studies of human branched-chain amino acid aminotransferases (hBCAT) revealed that the peptide bonds in both isoforms are all trans except for the bond between residues Gly338-Pro339. The active site of the enzyme lies in the interface between the two domains. Like other transaminase enzymes (as well as many enzymes of other classes), BCATs require the cofactor pyridoxal-5'-phosphate (PLP) for activity. PLP has been found to change the conformation of aminotransferase enzymes, locking the conformation of the enzyme via a Schiff base (imine) linkage in a reaction between a lysine residue of the enzyme and the carbonyl group of the cofactor. This conformational change allows the substrates to bind to the active site pocket of the enzymes.
Sources: en.wikipedia.org
== Mechanism of action == The MeCP2 protein binds to forms of DNA that have been methylated. The MeCP2 protein then interacts with other proteins to form a complex that turns off the gene. MeCP2 prefers to bind to sites on the genome with a chemical alteration made to a cytosine (C) when it occurs in a particular DNA sequence, "CpG". This is a form of DNA methylation. Many genes have CpG islands, which frequently occur near the beginning of the gene. MECP2 does not bind to these islands in most cases, as they are not methylated. The expression of a few genes may be regulated through methylation of their CpG island, and MECP2 may play a role in a subset of these. Researchers have not yet determined which genes are targeted by the MeCP2 protein, but such genes are probably important for the normal function of the central nervous system. However, the first large-scale mapping of MECP2 binding sites in neurons found that only 6% of the binding sites are in CpG islands, and that 63% of MECP2-bound promoters are actively expressed and only 6% are highly methylated, indicating that MECP2's main function is something other than silencing methylated promoters. Once bound, MeCP2 will condense the chromatin structure, form a complex with histone deacetylases (HDAC), or block transcription factors directly. More recent studies have demonstrated that MeCP2 may also function as a transcriptional activator, through recruiting the transcription factor CREB1.
Alpha-synuclein primary structure is usually divided in three distinct domains: Residues 1-60: An amphipathic N-terminal region dominated by four 11-residue repeats including the consensus sequence KTKEGV. This sequence has a structural alpha helix propensity similar to apolipoproteins-binding domains. It is a highly conserved terminal that interacts with acidic lipid membranes, and all the discovered point mutations of the SNCA gene are located within this terminal. Residues 61-95: A central hydrophobic region which includes the non-amyloid-β component (NAC) region, involved in protein aggregation. This domain is unique to alpha-synuclein among the synuclein family. Residues 96-140: a highly acidic and proline-rich region which has no distinct structural propensity. This domain plays an important role in the function, solubility and interaction of alpha-synuclein with other proteins.
== Oxygen-18 == Oxygen-18 (18O, Ω) is one of the stable isotopes of oxygen, with roughly 0.20% abundance, and considered one of the environmental isotopes. Most 18O is produced when 14N (made abundant from CNO burning) captures a 4He nucleus, becoming 18F. This quickly (half-life around 110 minutes) beta decays to 18O making that isotope common in the helium-rich zones of stars. Temperatures on the order of 109 kelvins are needed to fuse oxygen into sulfur. Fluorine-18 is usually produced by irradiation of 18O-enriched water with high-energy (about 18 MeV) protons prepared in a cyclotron or a linear accelerator, yielding an aqueous solution containing 18F as fluoride ion. This solution is then used for rapid synthesis of a labeled molecule, often with the fluorine atom replacing a hydroxy group. The labeled molecules or radiopharmaceuticals have to be synthesized after the radiofluorine is prepared, as the high energy proton radiation would destroy the molecules. Large amounts of oxygen-18 enriched water are used in positron emission tomography centers, for on-site production of 18F-labeled fluorodeoxyglucose (FDG). Measurements of the 18O/16O ratio (known as δ18O) are often used in paleoclimatology. Water molecules with a lighter isotope are slightly more likely to evaporate and less likely to fall as precipitation, so Earth's freshwater and polar ice have slightly less (0.1981%) 18O than air (0.204%) or seawater (0.1995%). This disparity allows the study of historical temperature patterns via the analysis of ice cores.
Sources: en.wikipedia.org
== External links == Austrian Centre of Industrial Biotechnology official website The Centre of Excellence for Biocatalysis - CoEBio3 The University of Exeter - Biocatalysis Centre Center for Biocatalysis and Bioprocessing - The University of Iowa TU Delft - Biocatalysis & Organic Chemistry (BOC) KTH Stockholm - Biocatalysis Research Group Institute of Technical Biocatalysis at the Hamburg University of Technology (TUHH) Biocascades Project
Wing Commander (now Group Captain) Christopher Hugh Moran, , (5202768). Wing Commander Stephen Ronald Sims (5203336). Wing Commander Robert Adrian Williams (5204463). Civil Division Mavis Ainsworth, lately Director, School of Cultural Studies, Sheffield Hallam University. For services to Education. Edward Aldridge, , Member, Moray Council. For services to Local Government. Graeme Yorkston Alexander, Chief Executive Officer, Devro International plc. For services to the Food Industry. Anthony Paul Allen, County Trading Standards Officer, East Sussex County Council. For services to Trading Standards and to Consumer Protection. Elizabeth Anne Allen, lately Director of Nursing, North West Anglia Healthcare Trust. For services to Health Care. Ian George Allen, Valuation Principal, Board of Inland Revenue. William Claude Allington. For political and public service. Professor Richard Edward Allsop, Professor of Transport Studies, University College London. For services to Traffic Management and Road Safety. John Victor Ronald Anderson. For political service. D. Michael Archer. For services to the Advisory Board for Redundant Churches. John D. Ault, Chair, Corporation of Yeovil College. For services to Education. David Bailey, Director of Development, London Underground. For services to Public Transport in London. Professor Andrew David Bain, Board Member, Scottish Enterprise. For services to the Scottish Economy. Edward John Meldrum Ball, lately Director, Oil Companies International Marine Forum. For services to Maritime Safety to the Environment. Helen Rae Bamber.
Larger doses do not appear to increase risks in this population. A broader retrospective study found that the rate of hyperkalemia in gender-diverse individuals is correlated with age, with those above 45 years old being more at risk. The finding suggests that patients below or at 45 years old without other conditions that affect potassium handling can be spared from routine monitoring.
== ATP analogues == Biochemistry laboratories often use in vitro studies to explore ATP-dependent molecular processes. ATP analogs are also used in X-ray crystallography to determine a protein structure in complex with ATP, often together with other substrates. Enzyme inhibitors of ATP-dependent enzymes such as kinases are needed to examine the binding sites and transition states involved in ATP-dependent reactions. Most useful ATP analogs cannot be hydrolyzed as ATP would be; instead, they trap the enzyme in a structure closely related to the ATP-bound state. Adenosine 5′-(γ-thiotriphosphate) is an extremely common ATP analog in which one of the gamma-phosphate oxygens is replaced by a sulfur atom; this anion is hydrolyzed at a dramatically slower rate than ATP itself and functions as an inhibitor of ATP-dependent processes. In crystallographic studies, hydrolysis transition states are modeled by the bound vanadate ion. Caution is warranted in interpreting the results of experiments using ATP analogs, since some enzymes can hydrolyze them at appreciable rates at high concentration.
Sources: en.wikipedia.org
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.
Cycling between frozen and thawed states promotes aggregation and can reduce the amount of soluble peptide. Adsorption to container walls also removes material from solution over time. Suppliers generally recommend aliquoting before freezing to limit the number of cycles.
A typical certificate lists lot number, appearance, purity by chromatographic area, identity confirmation and the analytical methods used. Some suppliers add endotoxin or residual solvent results. The document describes the tested lot only and does not extend to other batches.
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.